Forest Laboratories Announces Positive Results From Phase III Clinical Studies Of Ceftaroline For The Treatment Of Complicated Skin Infections
Jun 30th 2008Drug InformationMRSA / Drug Resistance
Forest Laboratories, Inc. (NYSE: FRX) announced positive results from two globally conducted, multi-center Phase III studies of ceftaroline, a broad-spectrum cephalosporin with activity against gram-positive bacteria, such as MRSA and gram negative bacteria, for the treatment of complicated skin and skin structure infections (cSSSI).
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
